Home › Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated With Ziarco's Lead Compound ZPL-389
 

Keywords :   


Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated With Ziarco's Lead Compound ZPL-389

2016-02-03 02:06:37| drugdiscoveryonline Home Page

Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, recently announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389

Tags: study lead phase initiated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.10Perfect storm blocking thousands of desperately needed social homes
07.10Hurricane Milton Public Advisory Number 6A
07.10Summary for Hurricane Milton (AT4/AL142024)
07.10Atlantic Tropical Weather Outlook
07.10Eastern North Pacific Tropical Weather Outlook
07.10Can selling off homes for $1 solve urban blight?
06.10Hurricane Milton Potential Storm Surge Flooding Map
06.10Hurricane Milton Probabilistic Storm Surge Graphics
More »